155 related articles for article (PubMed ID: 25386667)
1. N-cadherin, beta-catenin and connexin 43 expression in astrocytic tumours of various grades.
Reszec J; Szkudlarek M; Hermanowicz A; Bernaczyk PS; Mariak Z; Chyczewski L
Histol Histopathol; 2015 Mar; 30(3):361-71. PubMed ID: 25386667
[TBL] [Abstract][Full Text] [Related]
2. Relationship between the expression of E-, N-cadherins and beta-catenin and tumor grade in astrocytomas.
Utsuki S; Sato Y; Oka H; Tsuchiya B; Suzuki S; Fujii K
J Neurooncol; 2002 May; 57(3):187-92. PubMed ID: 12125981
[TBL] [Abstract][Full Text] [Related]
3. Expression of cadherin and CSF dissemination in malignant astrocytic tumors.
Asano K; Kubo O; Tajika Y; Takakura K; Suzuki S
Neurosurg Rev; 2000 Mar; 23(1):39-44. PubMed ID: 10809486
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of cyclin A in astrocytic tumours.
Chakrabarty A; Bridges LR
Neuropathol Appl Neurobiol; 1998 Jun; 24(3):239-45. PubMed ID: 9717190
[TBL] [Abstract][Full Text] [Related]
5. Expression of N-cadherin and alpha-catenin in astrocytomas and glioblastomas.
Shinoura N; Paradies NE; Warnick RE; Chen H; Larson JJ; Tew JJ; Simon M; Lynch RA; Kanai Y; Hirohashi S
Br J Cancer; 1995 Sep; 72(3):627-33. PubMed ID: 7669572
[TBL] [Abstract][Full Text] [Related]
6. The glucose transporter and blood-brain barrier of human brain tumors.
Guerin C; Laterra J; Hruban RH; Brem H; Drewes LR; Goldstein GW
Ann Neurol; 1990 Dec; 28(6):758-65. PubMed ID: 2178329
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of S100 calcium-binding proteins characterizes distinct clinical entities in both WHO grade II and III astrocytic tumours.
Camby I; Lefranc F; Titeca G; Neuci S; Fastrez M; Dedecken L; Schäfer BW; Brotchi J; Heizmann CW; Pochet R; Salmon I; Kiss R; Decaestecker C
Neuropathol Appl Neurobiol; 2000 Feb; 26(1):76-90. PubMed ID: 10736069
[TBL] [Abstract][Full Text] [Related]
8. Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration.
Camby I; Belot N; Rorive S; Lefranc F; Maurage CA; Lahm H; Kaltner H; Hadari Y; Ruchoux MM; Brotchi J; Zick Y; Salmon I; Gabius HJ; Kiss R
Brain Pathol; 2001 Jan; 11(1):12-26. PubMed ID: 11145198
[TBL] [Abstract][Full Text] [Related]
9. WT1 Clone 6F-H2 Cytoplasmic Expression Differentiates Astrocytic Tumors from Astrogliosis and Associates with Tumor Grade, Histopathology, IDH1 Status, Apoptotic and Proliferative Indices: A Tissue Microarray Study.
Abd El-Hafez A; Ismail Hany HSED
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2403-2413. PubMed ID: 32856872
[TBL] [Abstract][Full Text] [Related]
10. Increased endothelial expression of transglutaminase in glioblastomas.
Hilton DA; Love S; Barber R
Neuropathol Appl Neurobiol; 1997 Dec; 23(6):507-11. PubMed ID: 9460717
[TBL] [Abstract][Full Text] [Related]
11. Pathologic analysis of primary brain tumors.
McComb RD; Burger PC
Neurol Clin; 1985 Nov; 3(4):711-28. PubMed ID: 3001488
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis in cerebral astrocytic tumours and its relationship to expression of the bcl-2 and p53 proteins.
Ellison DW; Steart PV; Gatter KC; Weller RO
Neuropathol Appl Neurobiol; 1995 Aug; 21(4):352-61. PubMed ID: 7494604
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of metallothionein in astrocytic tumors in relation to tumor grade, proliferative potential, and survival.
Hiura T; Khalid H; Yamashita H; Tokunaga Y; Yasunaga A; Shibata S
Cancer; 1998 Dec; 83(11):2361-9. PubMed ID: 9840536
[TBL] [Abstract][Full Text] [Related]
14. Supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas are characterized by a differential expression of S100 proteins.
Camby I; Nagy N; Lopes MB; Schäfer BW; Maurage CA; Ruchoux MM; Murmann P; Pochet R; Heizmann CW; Brotchi J; Salmon I; Kiss R; Decaestecker C
Brain Pathol; 1999 Jan; 9(1):1-19. PubMed ID: 9989446
[TBL] [Abstract][Full Text] [Related]
15. Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis.
Kajiwara Y; Yamasaki F; Hama S; Yahara K; Yoshioka H; Sugiyama K; Arita K; Kurisu K
Cancer; 2003 Feb; 97(4):1077-83. PubMed ID: 12569609
[TBL] [Abstract][Full Text] [Related]
16. Coexpression of epidermal growth factor receptor protein and c-erbB-2 oncoprotein in human astrocytic tumors. An immunohistochemical study.
Dietzmann K; von Bossanyi P
Zentralbl Pathol; 1994 Nov; 140(4-5):335-41. PubMed ID: 7826981
[TBL] [Abstract][Full Text] [Related]
17. Endothelial nitric oxide synthase expression in tumor vasculature is correlated with malignancy in human supratentorial astrocytic tumors.
Iwata S; Nakagawa K; Harada H; Oka Y; Kumon Y; Sakaki S
Neurosurgery; 1999 Jul; 45(1):24-8; discussion 29. PubMed ID: 10414562
[TBL] [Abstract][Full Text] [Related]
18. Distinct differences in binding capacity to saccharide epitopes in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas, and glioblastomas.
Camby I; Decaestecker C; Gordower L; DeDecker R; Kacem Y; Lemmers A; Siebert HC; Bovin NV; Wesseling P; Danguy A; Salmon I; Gabius HJ; Kiss R
J Neuropathol Exp Neurol; 2001 Jan; 60(1):75-84. PubMed ID: 11202177
[TBL] [Abstract][Full Text] [Related]
19. Identification of cadherin-11 down-regulation as a common response of astrocytoma cells to transforming growth factor-alpha.
Zhou R; Skalli O
Differentiation; 2000 Dec; 66(4-5):165-72. PubMed ID: 11269942
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of Hsp-27 in astrocytic brain tumors: an immunohistochemical study.
Assimakopoulou M; Sotiropoulou-Bonikou G; Maraziotis T; Varakis I
Anticancer Res; 1997; 17(4A):2677-82. PubMed ID: 9252700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
